Geneva Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Geneva Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.4M	Sell	91,136 -3,693	-4%	-$583K	4.3%	4
2026 Q2	$15M	Buy	+94,829	New	+$12.8M	4%	5
2026 Q1	–	Sell	-74,465	Closed	-$9.08M	–	84
2025 Q4	$9.08M	Buy	+74,465	New	+$8.54M	3.23%	13

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return

Investure LLC Charlottesville, Virginia $1.83B AUM 14.32% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Geneva Partners's XBI Position: Q3 2026 in Review

Geneva Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.9% in Q3 2026, selling an estimated $583K and leaving 91,136 shares worth $14.4M. The position accounts for 4.3% of the portfolio, ranked #4.

Geneva Partners first reported a position in XBI in Q4 2025 and has held it in 3 quarters since. The position peaked at $15M in Q2 2026. 595 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Geneva Partners held 91,136 shares of State Street SPDR S&P Biotech ETF worth $14.4M as of Q3 2026.
Geneva Partners sold 3,693 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $583K.
State Street SPDR S&P Biotech ETF made up 4.3% of Geneva Partners's portfolio in Q3 2026, its #4 holding.
Geneva Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 3 quarters since.
Geneva Partners's State Street SPDR S&P Biotech ETF position peaked at $15M in Q2 2026.
595 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Geneva Partners's 13F filing for Q3 2026, filed 26 Oct 2026.